Moleculin Biotech

Moleculin Biotech PEG

The PEG Ratio (Price/Earnings-to-Growth) of Moleculin Biotech (MBRX) as of Nov 4, 2026 is -0.01. In the previous year, PEG Ratio (Price/Earnings-to-Growth) was -0.03 — a change of -61.08% (higher).

PEG

-0.01

YoY

-61.08%

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Moleculin Biotech is 2025 -0.01 . PEG Ratio (Price/Earnings-to-Growth) of Moleculin Biotech was 2024 -0.03 . It decreases by -61.08% higher compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Moleculin Biotech Stock analysis

What does Moleculin Biotech do? Moleculin Biotech Inc is a clinical-stage pharmaceutical company focused on developing treatments for cancers. Its drug candidates include Annamycin for relapsed or refractory acute myeloid leukemia and lung metastases, WP1066 as a p-STAT3 inhibitor targeting brain tumors and pancreatic cancer, WP1220 for cutaneous T-cell lymphoma, and WP1732, WP1122, and WP1234 for AML, pancreatic cancer, and brain tumors through glycolysis inhibition. The company generates revenue through the development and potential commercialization of these clinical-stage drugs, targeting oncology specialists and healthcare providers in the pharmaceutical sector. Moleculin's products are positioned for late-stage clinical trials with potential partnerships for drug development and commercialization. The company's primary revenue stream comes from the progression of its drug candidates through clinical trials, with potential future sales once regulatory approvals are secured. Annamycin, WP1066, WP1220, WP1732, WP1122, and WP1234 are the key products under development, each targeting specific cancer types such as AML, brain tumors, pancreatic cancer, and cutaneous T-cell lymphoma. Healthcare providers and oncology specialists are the primary buyers of these future products, as they will prescribe them to patients in clinical settings. Moleculin Biotech's business model relies on advancing its pipeline of oncology-focused drug candidates through clinical trials, with the goal of securing partnerships or licensing agreements with larger pharmaceutical companies for further development and commercialization. The company's products are designed to address unmet medical needs in cancer treatment, targeting segments including hematological malignancies, solid tumors, and skin cancers. Revenue is anticipated once drugs receive regulatory approval and enter the market, with current focus on completing clinical trials to demonstrate efficacy and safety. Moleculin Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moleculin Biotech stock

PEG Ratio (Price/Earnings-to-Growth) of Moleculin Biotech is -0.01 in 2025.

PEG Ratio (Price/Earnings-to-Growth) of Moleculin Biotech changed from -0.03 to -0.01, representing a -61.08% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Moleculin Biotech since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Moleculin Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Moleculin Biotech

All Key Metrics — Moleculin Biotech